D
Daniela Russo
H指数:12
被引数:553
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Somatic BRCA1 and BRCA2 detection in Homologous Recombination Deficiency testing: concordance of four sequencing workflows with the Myriad myChoice® companion diagnostic
体细胞BRCA1和BRCA2检测在同源重组缺陷测试中的应用:四种测序工作流与Myriad myChoice®伴随诊断的一致性
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析
ESMO Open
IF8.3
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial
肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin plus paclitaxel/avelumab (MITO-END3 trial)
外周单核细胞源性抑制性细胞与单中心接受卡铂联合紫杉醇/阿维单抗治疗子宫内膜癌患者分子亚型的相关性(MITO-END3试验)
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells
CXCR4拮抗剂R54靶向人类卵巢癌细胞中的上皮-间质转化(EMT)。
PLOS ONE
IF2.6
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study
接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

